The hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, are crucial for HCV assembly and entry, and are promising vaccine antigens. However, they are challenging to study because of technical difficulties in protein production and in quality control for protein folding and glycosylation. To study E1 and E2 in different experimental systems, e.g. infected cells, virus culture, virus-like particles, and clinical samples, a standardized method to accurately quantify the glycoproteins will be essential for most research projects. Here we outline a sensitive assay based on dual-color fluorescence immunoblot and the Odyssey imaging system to detect and quantify HCV E1 and E2 glycoproteins either using a purified E1E2 complex, or an engineered protein standard containing E1 and E2 at equal molar ratio. The method is capable of simultaneously detecting and quantifying as little as 7 ng of E1 and 5 ng of E2 in HCV pseudoparticles, and will be useful to quantify E1 and E2 from a wide variety of samples.
E1 E2 Glycoprotein Immunoblot Protein standard Antibody
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
This work was supported by NIH grants AI079031, AI106005, AI123365, and AI123861.
Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM (1994) Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 68:6147–6160PubMedPubMedCentralGoogle Scholar
Duvet S, Cocquerel L, Pillez A, Cacan R, Verbert A, Moradpour D et al (1998) Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J Biol Chem 273:32088–32095CrossRefGoogle Scholar
Rouille Y, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E et al (2006) Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol 80:2832–2841CrossRefGoogle Scholar
Lindenbach BD, Rice CM (2013) The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 11:688–700CrossRefGoogle Scholar
Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J (2010) Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 84:10159–10168CrossRefGoogle Scholar
Clayton RF, Owsianka A, Aitken J, Graham S, Bhella D, Patel AH (2002) Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol 76:7672–7682CrossRefGoogle Scholar
Sandrin V, Boulanger P, Penin F, Granier C, Cosset FL, Bartosch B (2005) Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. J Gen Virol 86:3189–3199CrossRefGoogle Scholar
Piver E, Boyer A, Gaillard J, Bull A, Beaumont E, Roingeard P et al (2017) Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture. Gut 66:1487–1495CrossRefGoogle Scholar
Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A (1992) Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol 181:293–300CrossRefGoogle Scholar
Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL (2006) Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 80:2418–2428CrossRefGoogle Scholar
Ruwona TB, Giang E, Nieusma T, Law M (2014) Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. J Virol 88:10459–10471CrossRefGoogle Scholar
Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J et al (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 109:6205–6210CrossRefGoogle Scholar
Keck ZY, Sung VM, Perkins S, Rowe J, Paul S, Liang TJ et al (2004) Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol 78:7257–7263CrossRefGoogle Scholar
Broering TJ, Garrity KA, Boatright NK, Sloan SE, Sandor F, Thomas WD Jr et al (2009) Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 83:12473–12482CrossRefGoogle Scholar
Li Y, Pierce BG, Wang Q, Keck ZY, Fuerst TR, Foung SK et al (2015) Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. J Biol Chem 290:10117–10125CrossRefGoogle Scholar
Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH (2001) Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 82:1877–1883CrossRefGoogle Scholar
Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C et al (2007) Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 25:7773–7784CrossRefGoogle Scholar
Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D et al (2010) Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28:6367–6373CrossRefGoogle Scholar
Triyatni M, Vergalla J, Davis AR, Hadlock KG, Foung SK, Liang TJ (2002) Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 298:124–132CrossRefGoogle Scholar